Skip to main content
Fig. 6 | Journal of Nanobiotechnology

Fig. 6

From: A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (−) prostate cancer specific therapy

Fig. 6

MTT assay of all drug formulation against PC-3 cells or LNCaP cells. a The relative cell viability of PC-3 cells and LNCaP cells after treated with PEG-b-P(LL-g-TK) for 48 h. b The relative cell viability of PC-3 cells and LNCaP cells after treated with α-TOS for 48 h. c, d The relative cell viability of LNCaP cells (c) and PC-3 cells (d) after treated with ATD-NPs and TD-NPs for 48 h. e, f The relative cell viability of PC-3 cells (e) and LNCaP cells (f) after treated with DOX, AD-NPs, AD-NPs + α-TOS, and ATD-NPs for 48 h. Data showed mean ± SD, n = 6. ***p < 0.001

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us